A detailed history of Vanguard Group Inc transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 13,536,832 shares of TGTX stock, worth $241 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13,536,832
Previous 13,670,944 0.98%
Holding current value
$241 Million
Previous $233 Million 11.82%
% of portfolio
0.0%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

SELL
$13.02 - $21.3 $1.75 Million - $2.86 Million
-134,112 Reduced 0.98%
13,536,832 $206 Million
Q4 2023

Feb 14, 2024

BUY
$6.68 - $18.81 $1.33 Million - $3.76 Million
199,770 Added 1.48%
13,670,944 $233 Million
Q3 2023

Nov 14, 2023

BUY
$8.36 - $26.5 $134,378 - $425,961
16,074 Added 0.12%
13,471,174 $113 Million
Q2 2023

Aug 14, 2023

BUY
$15.48 - $35.0 $1.17 Million - $2.65 Million
75,593 Added 0.56%
13,455,100 $334 Million
Q1 2023

May 15, 2023

SELL
$10.23 - $19.34 $21.7 Million - $41.1 Million
-2,123,257 Reduced 13.7%
13,379,507 $201 Million
Q4 2022

Feb 10, 2023

BUY
$5.01 - $11.83 $3.79 Million - $8.95 Million
756,372 Added 5.13%
15,502,764 $183 Million
Q3 2022

Nov 14, 2022

BUY
$4.57 - $8.4 $7.89 Million - $14.5 Million
1,725,560 Added 13.25%
14,746,392 $87.3 Million
Q2 2022

Aug 12, 2022

BUY
$3.74 - $10.66 $3.33 Million - $9.49 Million
889,869 Added 7.34%
13,020,832 $55.3 Million
Q1 2022

May 13, 2022

BUY
$7.81 - $20.45 $308,698 - $808,306
39,526 Added 0.33%
12,130,963 $115 Million
Q4 2021

Feb 14, 2022

BUY
$15.2 - $35.51 $897,727 - $2.1 Million
59,061 Added 0.49%
12,091,437 $230 Million
Q3 2021

Nov 12, 2021

BUY
$21.78 - $40.45 $6.69 Million - $12.4 Million
307,032 Added 2.62%
12,032,376 $400 Million
Q2 2021

Aug 13, 2021

BUY
$32.5 - $48.96 $381 Million - $574 Million
11,725,344 New
11,725,344 $455 Million

Others Institutions Holding TGTX

About TG THERAPEUTICS, INC.


  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $2.58B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.